Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Company Overview

Verrica Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions. The company conducts its clinical trials primarily in the United States and has engaged with regulatory authorities in Europe to support potential future filings. Verrica collaborates with contract research organizations and academic partners to execute its development programs and gather data on safety and efficacy.

Founded in 2020 as a strategic spin-out from Aclaris Therapeutics, Verrica is headquartered in West Chester, Pennsylvania. The company’s management team brings deep expertise in dermatology drug development, clinical operations and commercial strategy. As Verrica moves toward potential product approvals, it aims to address significant unmet needs in pediatric and adult dermatology markets.

Key Stats

• Today's Range: $6.95 to $8.30
• 50-Day Range: $4.38 to $7.16
• 52-Week Range: $3.28 to $9.82
• Volume: 311,056 shs
• Average Volume: 126,906 shs
• Market Capitalization: $138.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Reduce

Verrica Pharmaceuticals Stock Analysis - MarketRank™

Verrica Pharmaceuticals scored higher than 32% of companies evaluated by MarketBeat, and ranked 613th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Verrica Pharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.

Upside Potential

Verrica Pharmaceuticals has a consensus price target of $17.00, representing about 108.7% upside from its current price of $8.15.

Amount of Analyst Coverage

Verrica Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.24) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Verrica Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Verrica Pharmaceuticals is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Verrica Pharmaceuticals has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.36% of the float of Verrica Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 6.81.

Change versus previous month

Short interest in Verrica Pharmaceuticals has recently increased by 16.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Verrica Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Verrica Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.39

News Sentiment

Verrica Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Verrica Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for VRCA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

54.00% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VRCA Stock Analysis - Frequently Asked Questions

How have VRCA shares performed this year?

Verrica Pharmaceuticals' stock was trading at $8.31 at the beginning of 2026. Since then, VRCA shares have decreased by 2.0% and is now trading at $8.1460.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) announced its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.08. The company had revenue of $5.09 million for the quarter, compared to analyst estimates of $4.52 million.
Read the conference call transcript.

When did Verrica Pharmaceuticals' stock split?

Verrica Pharmaceuticals's stock reverse split on the morning of Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Verrica Pharmaceuticals IPO?

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include Meta Platforms (META), Paycom Software (PAYC), Walt Disney (DIS), uniQure (QURE), Centrus Energy (LEU) and Clean Energy Fuels (CLNE).

Company Calendar

• Last Earnings: 3/11/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRCA
• CIK: 1660334
• Web: www.verrica.com
• Phone: (434) 453-3300
• Fax: N/A
• Employees: 40
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Verrica Pharmaceuticals: $17.00
• High Price Target: $17.00
• Low Price Target: $17.00
• Potential Upside/Downside: +110.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.89 million
• Net Margins: -50.27%
• Pretax Margin: -50.27%
• Return on Equity: N/A
• Return on Assets: -40.08%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.59
• Quick Ratio: 2.45

Sales & Book Value

• Annual Sales: $35.58 million
• Price / Sales: 3.89
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.55 per share
• Price / Book: 5.20

Miscellaneous

• Outstanding Shares: 17,180,000
• Free Float: 7,902,000
• Market Cap: $138.56 million
• Optionable: No Data
• Beta: 1.54